Dr Elizabeth O'Donnell speaks to ecancer about the real-world effectiveness of immunoglobulin replacement therapy on hypogammaglobulinemia and infectious complications in patients with multiple myeloma.

Her study investigates immunoglobulin replacement therapy in multiple myeloma patients, analysing data from over 6,000 individuals from 2010 to 2023.

It found that 471 patients received therapy, leading to an 8% treatment rate.

Post-therapy, there is a significant reduction in infection rates, with 64% of patients showing hypogammaglobulinemia.

The research emphasises the need for monitoring immunoglobulin levels to enhance patient outcomes.